➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 10,272,102

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,272,102
Title:Hydroxyalkyl starch for the treatment of hematological neoplasms
Abstract: The present invention relates to hydroxyalkyl starch or a pharmaceutical preparation thereof for the treatment of a hematological neoplasm, especially by effectively reducing proliferation rate of cancer cells and inhibiting cancer cell growth and wherein the hydroxyalkyl starch has a mean molecular weight (MW) above 20 and below 1300 kDa and a molar substitution (MS) in the range of from 0.1 to 1.5, wherein the alkylation may be an ethylation, propylation or butylation or mixes thereof; and wherein the alkyl may be further substituted.
Inventor(s): Westphal; Martin (Bad Homburg, DE), Baasner; Silke (Schoneck, DE)
Assignee: FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE)
Application Number:14/909,284
Patent Claims:see list of patent claims

Details for Patent 10,272,102

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial FRESENIUS KABI DEUTSCHLAND GMBH (Bad Homburg, DE) 2033-07-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
McKinsey
Johnson and Johnson
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.